Payment overview · 2025
General Payments
$189.83
9 reported records · 7 companies
Healthcare provider profile · identity verified
Keith A. Meyer, MD
Allopathic & Osteopathic Physicians|Family Medicine · AURORA, MO · NPI 1770667925
Verified facts
What the public records show
CMS Open Payments records show Keith A. Meyer, MD received $189.83 in general payments during 2025 across 9 reported records.
Abbott Laboratories accounted for 25.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.65 | 25.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.41 | 17.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.95 | 13.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.35 | 12.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.00 | 11.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.13 | 10.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.34 | 10.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $189.83 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $47.65 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 19 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 324 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 243 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 197 | 55 |
| Losartan Potassium | Losartan Potassium | 158 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 152 | 36 |
| Lisinopril | Lisinopril | 149 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 32 |
| Tramadol Hcl | Tramadol Hcl | 141 | 32 |
| Furosemide | Furosemide | 140 | 36 |
| Potassium Chloride | Potassium Chloride | 132 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 114 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 31 |
| Gabapentin | Gabapentin | 106 | 24 |
| Omeprazole | Omeprazole | 98 | 25 |
| Alprazolam | Alprazolam | 84 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 24 |
| Eliquis | Apixaban | 82 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 17 |
| Metformin Hcl | Metformin Hcl | 79 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 26 |
| Carvedilol | Carvedilol | 76 | 14 |
| Glipizide Er | Glipizide | 76 | 21 |
| Meloxicam | Meloxicam | 72 | 24 |
| Sertraline Hcl | Sertraline Hcl | 72 | 18 |
| Metformin Hcl Er | Metformin Hcl | 70 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 22 |
| Donepezil Hcl | Donepezil Hcl | 60 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 24 |
| Clonazepam | Clonazepam | 57 | suppressed |
| Temazepam | Temazepam | 57 | suppressed |
| Lovastatin | Lovastatin | 55 | 17 |
| Famotidine | Famotidine | 48 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 13 |
| Enalapril Maleate | Enalapril Maleate | 44 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 20 |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Glimepiride | Glimepiride | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 36 | 36 |
| Prednisone | Prednisone | 36 | 17 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 15 |
| Simvastatin | Simvastatin | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 21 |
| Lorazepam | Lorazepam | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 19 | 19 |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 13 |
| Jardiance | Empagliflozin | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 13 | 13 |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Matzim La | Diltiazem Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $189.83 · 9 records | Abbott Laboratories | ABRYSVO, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, FREESTYLE LIBRE, PREVNAR 20, REXULTI, The Cologuard Plus Collection Kit, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error